Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book provides an in-depth analysis of the mechanisms and biological consequences of genome rearrangements in bacteria. Genome rearrangements are a result of the actions of discrete genetic elements such as conjugative transposons, plasmids, phage, and non-conjugative transposons. Bacteria also contain systems to mediate genetic rearrangements such as the general recombination pathway and specialized endogenous recombination mechanisms. The biological effects of these rearrangements are far-reaching and impact on bacterial virulence, antibiotic resistance and the ability of bacteria to avoid the attentions of the host immune system (e.g. antigenic variation). These rearrangements also provide the raw material on which natural selection can act. Each chapter examines the mechanisms involved in genome rearrangements and the direct biological consequences of these events. This book is written by leading research workers and is an invaluable resource for graduate students and researchers in this field.

Bacterial genetics. --- Genetic recombination. --- Bacterial transformation. --- Transformation, Bacterial --- Transformation (Genetics) --- Cell transformation --- Genetic recombination --- Genetic transformation --- Microbial genetics --- Recombination, Genetic --- Chromosomes --- Recombinant DNA --- Bacteria --- Bacteriology --- Genetics

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

English drama --- Religion in literature --- Théâtre anglais --- Religion dans la littérature --- History and criticism --- Histoire et critique

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This second edition provides 21 new chapters on methods used in laboratories for investigating the physiology and molecular genetics of the pathogen Clostridium difficile. Chapters detail up-to -date experimental techniques for gene editing and transcriptional analysis which are used to investigate the fundamental biology of the organism and its virulence factors. Additional chapters describe development of potential new treatments including vaccines, bacteriophage and faecal transplantation. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Clostridium difficile: Methods and Protocols, Second Edition provides a comprehensive catalogue of molecular tools and techniques authored by the researchers who have developed them.

Immunology. --- Immunobiology --- Life sciences --- Serology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.

lysins --- bacteriophage therapy --- bacterial infection treatment --- biofilms --- immunology --- biocontrol --- regulatory issues

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.

lysins --- bacteriophage therapy --- bacterial infection treatment --- biofilms --- immunology --- biocontrol --- regulatory issues